What is Zacks Small Cap’s Forecast for QNRX FY2025 Earnings?

Quoin Pharmaceuticals, Ltd. (NASDAQ:QNRX) – Equities researchers at Zacks Small Cap boosted their FY2025 earnings per share (EPS) estimates for Quoin Pharmaceuticals in a research note issued on Monday, March 17th. Zacks Small Cap analyst M. Marin now anticipates that the company will post earnings of ($0.44) per share for the year, up from their prior estimate of ($2.00). The consensus estimate for Quoin Pharmaceuticals’ current full-year earnings is ($2.05) per share.

Quoin Pharmaceuticals Trading Down 3.2 %

Shares of QNRX stock opened at $0.29 on Thursday. Quoin Pharmaceuticals has a 1 year low of $0.27 and a 1 year high of $1.57. The firm’s 50 day moving average is $0.36 and its 200-day moving average is $0.55. The firm has a market capitalization of $1.46 million, a price-to-earnings ratio of -0.07 and a beta of 1.82.

Quoin Pharmaceuticals (NASDAQ:QNRX) last issued its quarterly earnings results on Thursday, March 13th. The company reported ($0.35) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.50) by $0.15.

Institutional Trading of Quoin Pharmaceuticals

Institutional investors and hedge funds have recently made changes to their positions in the business. Apollon Wealth Management LLC bought a new position in shares of Quoin Pharmaceuticals in the 4th quarter worth $52,000. Renaissance Technologies LLC increased its position in shares of Quoin Pharmaceuticals by 244.1% during the fourth quarter. Renaissance Technologies LLC now owns 133,122 shares of the company’s stock worth $87,000 after acquiring an additional 94,431 shares in the last quarter. Boothbay Fund Management LLC acquired a new stake in shares of Quoin Pharmaceuticals in the 4th quarter valued at about $53,000. Finally, Altium Capital Management LLC acquired a new stake in Quoin Pharmaceuticals in the 4th quarter valued at approximately $184,000. Institutional investors own 8.63% of the company’s stock.

Insider Buying and Selling

In other Quoin Pharmaceuticals news, Director Anthony James Culverwell bought 100,000 shares of the business’s stock in a transaction on Monday, December 23rd. The shares were bought at an average cost of $0.45 per share, for a total transaction of $45,000.00. Following the transaction, the director now owns 100,317 shares in the company, valued at approximately $45,142.65. This trade represents a 31,545.74 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CFO Gordon Dunn bought 122,221 shares of Quoin Pharmaceuticals stock in a transaction dated Monday, December 23rd. The stock was acquired at an average cost of $0.45 per share, for a total transaction of $54,999.45. Following the purchase, the chief financial officer now directly owns 151,077 shares in the company, valued at approximately $67,984.65. The trade was a 423.55 % increase in their position. The disclosure for this purchase can be found here. Insiders purchased 777,777 shares of company stock worth $350,000 in the last quarter. Insiders own 3.70% of the company’s stock.

About Quoin Pharmaceuticals

Quoin Pharmaceuticals, Ltd., a clinical stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases. Its lead product is QRX003, a topical lotion to treat Netherton Syndrome (NS). The company is also developing QRX004 for the treatment of recessive dystrophic epidermolysis bullosa; QRX007 to treat NS; and QRX008 for the treatment of scleroderma.